$23.22 Million in Sales Expected for Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) This Quarter

Brokerages predict that Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) will announce sales of $23.22 million for the current quarter, Zacks reports. Five analysts have provided estimates for Enanta Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $16.50 million and the highest estimate coming in at $27.13 million. Enanta Pharmaceuticals reported sales of $23.63 million during the same quarter last year, which indicates a negative year over year growth rate of 1.7%. The firm is expected to issue its next earnings results on Monday, November 22nd.

According to Zacks, analysts expect that Enanta Pharmaceuticals will report full year sales of $94.02 million for the current financial year, with estimates ranging from $81.66 million to $100.63 million. For the next year, analysts forecast that the firm will post sales of $101.12 million, with estimates ranging from $62.86 million to $128.65 million. Zacks Investment Research’s sales averages are a mean average based on a survey of analysts that that provide coverage for Enanta Pharmaceuticals.

Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its quarterly earnings results on Thursday, August 5th. The biotechnology company reported ($1.19) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.41) by $0.22. Enanta Pharmaceuticals had a negative return on equity of 14.86% and a negative net margin of 86.21%.

Several research firms have commented on ENTA. Royal Bank of Canada lowered their price target on shares of Enanta Pharmaceuticals from $52.00 to $50.00 and set a “sector perform” rating on the stock in a report on Friday, August 6th. SVB Leerink initiated coverage on shares of Enanta Pharmaceuticals in a research note on Thursday, September 9th. They set a “market perform” rating and a $55.00 target price on the stock. Zacks Investment Research raised shares of Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, August 10th. Finally, JMP Securities increased their target price on shares of Enanta Pharmaceuticals from $70.00 to $77.00 and gave the stock an “outperform” rating in a research note on Friday, August 6th. One research analyst has rated the stock with a sell rating, five have given a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Enanta Pharmaceuticals currently has a consensus rating of “Hold” and an average price target of $61.38.

Hedge funds have recently modified their holdings of the business. The PNC Financial Services Group Inc. increased its stake in Enanta Pharmaceuticals by 42.8% in the first quarter. The PNC Financial Services Group Inc. now owns 787 shares of the biotechnology company’s stock valued at $39,000 after purchasing an additional 236 shares during the period. State of Alaska Department of Revenue increased its stake in shares of Enanta Pharmaceuticals by 2.3% during the second quarter. State of Alaska Department of Revenue now owns 12,435 shares of the biotechnology company’s stock worth $547,000 after acquiring an additional 282 shares during the period. South Dakota Investment Council increased its stake in shares of Enanta Pharmaceuticals by 142.7% during the first quarter. South Dakota Investment Council now owns 16,746 shares of the biotechnology company’s stock worth $826,000 after acquiring an additional 9,846 shares during the period. Exchange Traded Concepts LLC increased its stake in shares of Enanta Pharmaceuticals by 10.5% during the second quarter. Exchange Traded Concepts LLC now owns 20,169 shares of the biotechnology company’s stock worth $888,000 after acquiring an additional 1,916 shares during the period. Finally, Fisher Asset Management LLC increased its stake in shares of Enanta Pharmaceuticals by 4.1% during the second quarter. Fisher Asset Management LLC now owns 6,601 shares of the biotechnology company’s stock worth $291,000 after acquiring an additional 258 shares during the period.

Shares of NASDAQ ENTA traded up $0.63 during mid-day trading on Tuesday, hitting $57.91. The stock had a trading volume of 91,838 shares, compared to its average volume of 145,030. The company has a 50 day moving average of $48.16 and a two-hundred day moving average of $48.85. Enanta Pharmaceuticals has a twelve month low of $40.32 and a twelve month high of $58.61. The firm has a market cap of $1.17 billion, a PE ratio of -13.95 and a beta of 0.43.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc is a biotechnology company, which engages in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. It produces clinical candidates which targets respiratory syncytial virus (RSV), hepatitis B virus (HBV), and non-alcoholic steatohepatitis (NASH) diseases.

Further Reading: The risks of owning bonds

Get a free copy of the Zacks research report on Enanta Pharmaceuticals (ENTA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Enanta Pharmaceuticals (NASDAQ:ENTA)

Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.